NA
Navidea Biopharmaceuticals, Inc.
NAVBQ · OTC
$0.00 -99.75% (-$0.04)
1M +0.00%
Market Cap $10.0K
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 0.15x
P/FCF N/A
P/B N/A
Growth
100 /100
Growing Rev. growth 35.11%
FCF growth N/A
Book val. growth N/A
Profitability
0 /100
Weak FCF margin 14,282.80%
Op. margin 21,402.10%
Gross margin 259.40%
Quality
57 /100
Average ROA 347.18%
Asset turnover 0.02x
ROIC 280.59%
Debt
50 /100
Moderate Int. coverage -12.82x
Net debt/EBITDA -0.03x
Current ratio 0.32x
Stability
28 /100
Unstable Profitable years 0
EPS volatility 39.84%
Beta -4.82x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na NAVBQ
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Craig A. Dais
Employees
11
Headquarters
Dublin
Nadcházející události
16 LIS
Earnings
Upcoming earnings report